{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:39:18Z","timestamp":1761183558847,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006441","name":"Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006441","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.jphs.2019.05.006","type":"journal-article","created":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T11:02:30Z","timestamp":1558954950000},"page":"197-200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Characterization of binding of antipsychotics to muscarinic receptors using mouse cerebral cortex"],"prefix":"10.1016","volume":"140","author":[{"given":"Keisuke","family":"Obara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saki","family":"Horiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toma","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Ikarashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiko","family":"Yamaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Yoshio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jphs.2019.05.006_bib1","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40264-014-0170-y","article-title":"Are the safety profiles of antipsychotic drugs used in dementia the same? An updated review of observational studies","volume":"37","author":"Trifiro","year":"2014","journal-title":"Drug Saf"},{"key":"10.1016\/j.jphs.2019.05.006_bib2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/ene.13439","article-title":"Alzheimer's disease","volume":"25","author":"Lane","year":"2018","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jphs.2019.05.006_bib3","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/0024-3205(88)90519-X","article-title":"Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites","volume":"43","author":"Hals","year":"1988","journal-title":"Life Sci"},{"key":"10.1016\/j.jphs.2019.05.006_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","article-title":"Binding of antipsychotic drugs to human brain receptors: focus on newer generation compounds","volume":"68","author":"Richelson","year":"2000","journal-title":"Life Sci"},{"key":"10.1016\/j.jphs.2019.05.006_bib5","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1248\/bpb.b18-00829","article-title":"Assessment of inhibitory effects of hypnotics on acetylcholine-induced contractions in isolated rat urinary bladder smooth muscle","volume":"42","author":"Obara","year":"2019","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.jphs.2019.05.006_bib6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0379-0738(01)00483-2","article-title":"Drug and chemical blood-level data 2001","volume":"122","author":"Winek","year":"2001","journal-title":"Forensic Sci Int"},{"key":"10.1016\/j.jphs.2019.05.006_bib7","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/bmc.1725","article-title":"Simultaneous determination of prochlorperazine and its metabolites in human plasma using isocratic liquid chromatography tandem mass spectrometry","volume":"26","author":"Tashiro","year":"2012","journal-title":"Biomed Chromatogr"},{"key":"10.1016\/j.jphs.2019.05.006_bib8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1046\/j.1440-1819.1998.00421.x","article-title":"Plasma concentrations of timiperone and its reduced metabolite in the patients on timiperone","volume":"52","author":"Shimoda","year":"1998","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.jphs.2019.05.006_bib9","first-page":"1595","article-title":"Pharmacokinetics and metabolism of 2-chloro-11-(2-dimethylaminoethoxy)-dibenzo[b,f]thiepine (zotepine) in rat, mouse, dog and man","volume":"29","author":"Noda","year":"1979","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.jphs.2019.05.006_bib10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/JCP.0000000000000319","article-title":"The influence of the CYP3A4*22 polymorphism and CYP2D6 polymorphisms on serum concentrations of aripiprazole, haloperidol, pimozide, and risperidone in psychiatric patients","volume":"35","author":"van der Weide","year":"2015","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.jphs.2019.05.006_bib11","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/hup.1124","article-title":"The relationship between the daily dose, the plasma concentration of blonanserin, and its plasma anti-dopamine D2 and anti-serotonin 5-HT2A activity","volume":"25","author":"Suzuki","year":"2010","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.jphs.2019.05.006_bib12","doi-asserted-by":"crossref","first-page":"e3928","DOI":"10.1002\/bmc.3928","article-title":"Development of a UPLC-MS\/MS method for routine therapeutic drug monitoring of aripiprazole, amisulpride, olanzapine, paliperidone and ziprasidone with a discussion of their therapeutic reference ranges for Chinese patients","volume":"31","author":"Wang","year":"2017","journal-title":"Biomed Chromatogr"},{"key":"10.1016\/j.jphs.2019.05.006_bib13","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/JCP.0000000000000070","article-title":"The influence of the CYP3A4*22 polymorphism on serum concentration of quetiapine in psychiatric patients","volume":"34","author":"van der Weide","year":"2014","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.jphs.2019.05.006_bib14","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1176\/appi.ajp.2015.14050673","article-title":"Prediction of working memory performance in schizophrenia by plasma ratio of clozapine to N-desmethylclozapine","volume":"172","author":"Rajji","year":"2015","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jphs.2019.05.006_bib15","first-page":"417","article-title":"Plasma concentrations of antipsychotic drugs in psychiatric inpatients","volume":"51","author":"Tokunaga","year":"1997","journal-title":"Nihon Hoigaku Zasshi"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861319340617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861319340617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:58:41Z","timestamp":1761163121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861319340617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S1347861319340617"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2019.05.006","relation":{},"ISSN":["1347-8613"],"issn-type":[{"type":"print","value":"1347-8613"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of binding of antipsychotics to muscarinic receptors using mouse cerebral cortex","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2019.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}